ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Prof Walter Weder speaks to ecancer at BGICC 2023 about the role of lymph nodes in stage 3 lung cancer.
He outlines that data showed after neoadjuvant chemo or chemoradiation treatment the number of complete response in single or multiple stations was the same. Also the number of persistent positive lymph nodes was the same for single and multiple stations.
Prof Weder summarises surgical decisions about resectable disease should be done after the neoadjuvant treatment and not before.
The last study was on the role of lymph node extent in the mediastinum in stage 3 disease. Guidelines such as that only a single station is resectable and all other, more than one station, is considered unresectable. However, our data show that after neoadjuvant chemo or chemoradiation treatment that the number of complete responses in single or in multiple stations is exactly the same. Also, the number of persistent positive lymph nodes is the same for single and multiple stations which comes to the conclusion that the decision about resectable disease has to be done after neoadjuvant treatment and not before and a larger number of patients should be included into such a neoadjuvant treatment followed by surgery.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
The role of multidisciplinary tumour board in managing stage 3 lung cancer
COMMENT: Women Who Conquer Cancer